DUBLIN--(BUSINESS WIRE)--The "NS-065/NCNP-01 (Viltolarsen) - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
The report provides comprehensive insights about an investigational product for Duchenne Muscular Dystrophy in 7 Major Markets.
A detailed picture of the Viltolarsen in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.
The product details cover mechanism of action, dosage and administration, route of synthesis, and research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
NS-065/NCNP-01 (viltolarsen) is being developed by NS Pharma in phase III stage of development for the treatment of Duchenne Muscular Dystrophy. It is an antisense oligonucleotide with a novel morpholino backbone and molecule size. It is a Exon skipping therapy that are created to skip over the non-working part of the dystrophin gene and allow pieces of the puzzle to attach. It creates a smaller puzzle, but a puzzle that may produce some of the protein that muscles need to work properly.
The report provides insights into:
- A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
- Elaborated details on regulatory milestones and other development activities have been provided in this report.
- The report also highlights the drug research and development activity details across the United States, Europe and Japan.
- The report also covers the patents information with expiry timeline around Viltolarsen.
- The report contains forecasted sales for Viltolarsen till 2030.
- Comprehensive coverage of the late-stage emerging therapies (Phase III) for Duchenne Muscular Dystrophy.
- The report also features the SWOT analysis with analyst insights and key findings of Viltolarsen.
- In the coming years, the market scenario for Duchenne Muscular Dystrophy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Viltolarsen dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Other emerging products for Duchenne Muscular Dystrophy are giving market competition to Viltolarsen and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of Viltolarsen.
- Our in-depth analysis of the forecasted sales data of Viltolarsen from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Viltolarsen.
Key Questions Answered
- Which company is developing Viltolarsen along with the phase of the clinical study?
- What is the technology utilized in the development of Viltolarsen?
- What is the product type, route of administration and mechanism of action of Viltolarsen?
- What is the clinical trial status of the study and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Viltolarsen development?
- What are the key designations that have been granted to Viltolarsen?
- What is the forecasted market scenario of Viltolarsen?
- What is the history of Viltolarsen and what is its future?
- What is the forecasted sales of Viltolarsen in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- What are the other emerging products available and how these are giving competition to Viltolarsen?
- Which are the late-stage emerging therapies under development for the treatment of the Duchenne Muscular Dystrophy?
Key Topics Covered
1. Drug Overview
1.1. Product Detail
1.2. Mechanism of Action
1.3. Dosage and Administration
1.4. Research and Development Activity
1.4.1. Clinical Development
1.4.2. Safety and Efficacy
1.5. Other Development Activities
2. Market Assessment
2.1. 7MM Market Analysis
2.2. The United States Market
2.3. Germany Market
2.4. France Market
2.5. Italy Market
2.6. Spain Market
2.7. United Kingdom Market
2.8. Japan Market
3. SWOT Analysis
4. Analyst Views
5. Market Competitors
6. Other Emerging Therapies
List of Tables
Table 1 Viltolarsen, Description
Table 2 Viltolarsen, Clinical Trial Description
Table 3 Viltolarsen, 7MM Market Size from 2020 to 2030 (in Million USD)
Table 4 Market Competitors
Table 5 Other Emerging Therapies
List of Figures
Figure 1 The Development Timeline of VILTOLARSEN
Figure 2 Patent Details, VILTOLARSEN
Figure 3 Viltolarsen, 7MM Market Size from 2020 to 2030 (in Million USD)
Figure 4 Viltolarsen, US Market Size from 2020 to 2030 (in Millions USD)
Figure 5 Viltolarsen, EU5 Market Size from 2020 to 2030 (in Millions USD)
Figure 6 Viltolarsen, Japan Market Size from 2020 to 2030 (in Millions USD)
For more information about this report visit https://www.researchandmarkets.com/r/lc36t